AccelBio

Executive Summary

AccelBio is a Cambridge, USA-based biotechnology service provider specializing in robotic cell-based assays, primary and transgenic cell provision, and custom preclinical research services. Founded in 2016, the company leverages high-throughput robotics and molecular biology to support drug discovery, diagnostic testing, and regenerative medicine programs for biopharmaceutical clients. Its service portfolio includes custom neuroscience/RNA biology assays, high-throughput drug screening, and COVID-19 testing innovations. By offering scalable, automated solutions, AccelBio enables clients to accelerate target validation, lead optimization, and translational research while reducing costs and timelines. The company’s expertise in cell-based assays and transgenic models positions it as a key partner in the biologics, antibodies, and cell therapy space, addressing the growing demand for outsourced preclinical services in the US and globally.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation High-Throughput Screening Platform75% success
• Q4 2026Strategic Partnership with Major Pharma for Neuroscience Assays60% success
• Q2 2027Expansion of Gene Therapy and Cell Therapy Service Offerings70% success